Adding CNP-53 to macitentan or sotatercept also further reduced RV/(LV + IVS) ratios numerically as compared to monotherapy, but the difference did not reach statistical significance due to the already significant improvement with monotherapy in this model.
← all excerpts
Endothelial C-type natriuretic peptide/guanylyl cyclase-B signaling prevents pulmonary arterial hypertension.
1
—
—